LKB1, A New Biomarker in Breast Cancer - Journal of Cancer Therapy

JCT > Vol.7 No.10, October 2016

Journal of Cancer Therapy

Volume 7, Issue 10 (October 2016)

ISSN Print: 2151-1934 ISSN Online: 2151-1942

Google-based Impact Factor: 0.30 Citations h5-index & Ranking

LKB1, A New Biomarker in Breast Cancer ()

HTML XML

Download as PDF (Size: 657KB) PP. 690-699

DOI: 10.4236/jct.2016.710071 1,614 Downloads 3,654 Views Citations

Author(s)

Hanine Lattouf^1,2,3,4, Coralie Poulard⁵, Isabelle Treilleux⁶, Nader Hussein⁴, Mona Diab-Assaf⁴, Muriel Le Romancer^1,2,3*

Affiliation(s)

¹Inserm U1052, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
²CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, Lyon, France.
³Université Lyon 1, Lyon, France.
⁴Laboratory of Molecular and Cellular Biology, Doctoral School of Sciences and Technologies, Lebanese University, Beirut, Lebanon.
⁵Department of Biochemistry and Molecular Biology, Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
⁶Centre Léon Bérard, Pathology Department, Lyon, France.

ABSTRACT

Breast cancer is the most common cancer in women worldwide. Estrogen signaling pathways have been identified as efficient targets of breast cancer therapy, given their key role in promoting breast tumor growth. Agents blocking estrogen-mediated pathways are routinely used in clinical applications in patients displaying estrogen-sensitive breast cancer subtypes; however intrinsic or acquired resistance to treatment often occurs or develops, thus limiting their efficacy. This limitation has highlighted an imperative need to identify new predictive biomarkers. Recent findings have highlighted a role for the Liver Kinase B1 (LKB1) in breast cancer tumorigenesis. LKB1 is a serine/threonine kinase mutated in Peutz-Jeghers syndrome (PJS), implicated in many cellular processes including energy metabolism, cell polarization and cell cycle arrest and has also been shown to play an essential role as a tumor suppressor gene by negatively regulating the mTOR pathway. This review provides an overview of previous findings and ongoing research on LKB1, and substantiates the use of this kinase as a potential prognostic and predictive biomarker of breast cancer.

KEYWORDS

LKB1, Biomarker, Breast Cancer, Estrogen Signaling

Share and Cite:

Lattouf, H. , Poulard, C. , Treilleux, I. , Hussein, N. , Diab-Assaf, M. and Le Romancer, M. (2016) LKB1, A New Biomarker in Breast Cancer. Journal of Cancer Therapy, 7, 690-699. doi: 10.4236/jct.2016.710071.

Cited by